CORSEARCH
17.5.2024 00:01:38 CEST | Business Wire | Press release
Corsearch, leading provider of brand protection and trademark solutions, has today shared research predicting that the size of the global trade in counterfeit goods could reach €1.67 trillion by 2030, a 75% increase from that of 2023 and a growth 3.6 times higher than predicted for the global economy over the same period.1
Corsearch calculations estimate that counterfeits accounted for 3.3% of global trade in 2023, and will grow to 5% by 2030 - meaning €1 in every €20 spent globally on products could be spent on counterfeit goods.
The total displaced economic activity from counterfeiting in 2022 – namely the cost to brands and manufacturers – totalled €1.02 trillion, resulting in a loss of €162 billion to worldwide sales tax revenue, impacting up to 5.4m jobs.2
In addition to the negative global economic impact of counterfeiting, fake products have a damaging effect on the reputation of brands, reducing customer trust and risking consumer safety.
Corsearch has recognised the need for advanced innovations and solutions in brand protection to meet this challenge, and has today launched its latest technology platform, Corsearch Zeal. The platform uses AI to secure removal of fakes and counterfeit goods from the Internet whilst enabling Corsearch’s team of experts to focus on the most severe issues for brands and consumers and to find the source of the illicit activity.
Using the Corsearch Zeal platform, brands can go further to identify the source of the problem, reducing the losses and harm from counterfeit trade and protecting consumers.
Simon Baggs, President of Brand & Content Protection, Corsearch, commented:
"The rapid expansion of the counterfeiting industry could take up to 5% of the global goods economy by 2030 - posing a significant threat to brands. Urgent measures need to be taken, which is why we are today launching our new Corsearch Zeal platform. Technology enables vast swathes of data to be collated – enabling brands to collaborate to stop online sales whilst also targeting the source of the problem. Without this effort, we estimate that one in twenty euros will be spent on counterfeit goods by 2030, a worrying figure for brands already grappling with the problem in 2024.
“Corsearch Zeal shows our continued dedication to innovation and delivering unrivalled brand protection in the face of this escalating challenge. With Corsearch Zeal and our team of experts, we want to provide the most advanced solutions, enabling brands to work together to protect their consumers.”
For further information on Corsearch Zeal, read more here.
Notes to Editors
Methodology
Corsearch calculations are based on the below datapoints:
-
Total global trade in goods: $31 trillion (UN Conference on Trade & Development) (2023)
Total growth in global trade in goods through 2030: 2.3% (Boston Consulting Group)
Total trade in counterfeit goods, 2023: $1.023 trillion (OECD data) (2023) -
Employment loss: 4.2-5.4 million jobs (Frontier Economics)
Cost of displaced legitimate economic activity due to counterfeiting: $1,106 billion (Frontier Economics & Corsearch calculation) (2022)
Impact on sales tax revenue: $174 billion (Frontier Economics & Corsearch calculation) - 8.3% CAGR in counterfeit trade (Corsearch calculation, based on data from UN Conference on Trade & Development, OECD and EUIPO figures)
For currency conversion into EUR, FX Rates accurate as of 09/05/24
About Corsearch:
Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515226927/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
